Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00794417
- Locations
- ๐บ๐ธ
Stanford University Medical Center, Stanford, California, United States
๐บ๐ธPalm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States
๐บ๐ธKentucky Cancer Clinic, Hazard, Kentucky, United States
A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 939
- Registration Number
- NCT00789373
- Locations
- ๐ฌ๐ง
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle, United Kingdom
Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2009-08-03
- Lead Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Target Recruit Count
- 230
- Registration Number
- NCT00786331
- Locations
- ๐ฎ๐น
Azienda Istituti Ospitalieri di Cremona, UO di Oncologia Medica, Cremona, Italy
๐ฎ๐นAzienda Ospedaliera Ospedali Riuniti di Bergamo, UO di Oncologia Medica, Bergamo, Italy
๐ฎ๐นAzienda Sanitaria Ospedaliera S. Croce e Carle, UO di Oncologia Medica, Cuneo, Italy
Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2019-02-01
- Target Recruit Count
- 23
- Registration Number
- NCT00769600
- Locations
- ๐บ๐ธ
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
๐ธ๐ฌSingapore General Hospital, Tiong Bahru Estate, Singapore
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 939
- Registration Number
- NCT00762034
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States
ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
- Conditions
- Interventions
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 66
- Registration Number
- NCT00745875
- Locations
- ๐บ๐ฆ
Research Site, Uzngorod, Ukraine
๐ง๐ฌresearch Site, Pleven, Bulgaria
Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 50
- Registration Number
- NCT00741221
- Locations
- ๐ฌ๐ท
Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece
๐ฌ๐ทSismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens, Greece
๐ฌ๐ท401 Military Hospital, Medical Oncology Unit, Athens, Greece
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Morphotek
- Target Recruit Count
- 89
- Registration Number
- NCT00738582
- Locations
- ๐บ๐ธ
Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
๐บ๐ธUniversity of California, San Francisco, San Francisco, California, United States
๐ฉ๐ชAsklepios Fachkliniken Mรผchen-Gauting, Gauting, Germany
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918
- Conditions
- Interventions
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00733031
- Locations
- ๐บ๐ธ
Research Site, Nashville, Tennessee, United States
Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-11
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 8
- Registration Number
- NCT00732303
- Locations
- ๐บ๐ธ
Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธCommunity Regional Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธHematology Oncology Associates S.J., P.A., Mt. Holly, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.